Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Adalimumab Biosimilar Market: By Product: Exemptia, Adalirel, Cipleumab, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Value Chain Analysis; Competitive Landscape; Industry Events and Developments
Global Adalimumab Biosimilar Market Outlook
The global adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2022-2027, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America, Asia Pacific, and Europe to be the Significant Regional Markets for Adalimumab Biosimilar
North America is expected to be one of the largest markets, owing to numerous large-scale testing laboratories worldwide. The rising incidence of rheumatoid arthritis and the growing geriatric population are among the major factors which are fuelling the market expansion in North America.
Due to extensive commercial advancements and growing biotechnology corporations in the province, Asia Pacific is anticipated to register sturdy growth over the projection period. The increasing focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel the global adalimumab biosimilar industry in the region.
Europe is expected to grow faster due to the rise in approvals of the new biosimilars, the ageing population, and increasing investments in the research and development of the new adalimumab biosimilars. For instance, in October 2018, Amgen Inc. launched AMGEVITA, a biosimilar of adalimumab.
Adalimumab Biosimilar: Market Segmentation
Adalimumab is a monoclonal antibody used to treat autoimmune illnesses, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and others. It accomplishes this by blocking Tumour Necrosis Factor (TNF), a soluble inflammatory cytokine. This drug helps prevent further joint injury and preserve joint function by lowering joint swelling.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By product, the market includes:
- Exemptia
- Adalirel
- Cipleumab
- Others
The several distribution channels of the market are:
- Hospital Pharmacies
- Retail Pharmacies
- Others
The regional markets for the adalimumab biosimilar industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Proliferation of Skin Disorders Augmenting the Market Growth
The most frequent illnesses that harm human health are skin disorders. Many skin disorders lead to lifelong disfigurement, stigma, and disability, and treating them effectively has become a significant concern for health organizations. In this context, a biosimilar of adalimumab has emerged as a feasible therapy option for persistent skin conditions like eczema. This aspect can significantly increase the size of the global adalimumab biosimilar industry throughout the forecast period. The multiple advantages, especially in treating psoriasis, adalimumab biosimilar is a preferred option for tackling skin disorders. The rising geriatric population and increasing public and private investment in pharmaceuticals will propel the market growth. Regulatory approvals for novel products motivate other companies to invest more in research and development and produce new inventions. Some global adalimumab biosimilar industry competitors are already working on new product development and portfolio expansion. For example, through a licencing deal with Cadila Healthcare, Glenmark Pharmaceuticals introduced ADALY, its adalimumab biosimilar medicine, in Mumbai in January 2018.
Key Industry Players in the Global Adalimumab Biosimilar Market
The report gives a detailed analysis of the following key players in the global adalimumab biosimilar industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Alfred E. Tiefenbacher (GmbH & Co. KG)
- Amgen Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Cadila Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
- Reliance Life Sciences Private Limited
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Adalimumab Biosimilar Market Analysis
8.1 Key Industry Highlights
8.2 Global Adalimumab Biosimilar Historical Market (2017-2021)
8.3 Global Adalimumab Biosimilar Market Forecast (2022-2027)
8.4 Global Adalimumab Biosimilar Market by Product
8.4.1 Exemptia
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Adalirel
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Cipleumab
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Adalimumab Biosimilar Market by Distribution Channel
8.5.1 Hospital Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Retail Pharmacies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Others
8.6 Global Adalimumab Biosimilar Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Alfred E. Tiefenbacher (GmbH & Co. KG)
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Amgen Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Boehringer Ingelheim Pharmaceuticals, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Glenmark Pharmaceuticals Limited
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Cadila Pharmaceuticals Ltd.
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Torrent Pharmaceuticals Ltd.
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Reliance Life Sciences Private Limited
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global Adalimumab Biosimilar Market: Key Industry Highlights, 2017 and 2027
2. Global Adalimumab Biosimilar Historical Market: Breakup by Product (USD Million), 2017-2021
3. Global Adalimumab Biosimilar Market Forecast: Breakup by Product (USD Million), 2022-2027
4. Global Adalimumab Biosimilar Historical Market: Breakup by Distribution Channel (USD Million), 2017-2021
5. Global Adalimumab Biosimilar Market Forecast: Breakup by Distribution Channel (USD Million), 2022-2027
6. Global Adalimumab Biosimilar Historical Market: Breakup by Region (USD Million), 2017-2021
7. Global Adalimumab Biosimilar Market Forecast: Breakup by Region (USD Million), 2022-2027
8. North America Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2017-2021
9. North America Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Europe Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2017-2021
11. Europe Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Asia Pacific Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2017-2021
13. Asia Pacific Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Latin America Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2017-2021
15. Latin America Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Middle East and Africa Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2017-2021
17. Middle East and Africa Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Global Adalimumab Biosimilar Market Structure
Key Questions Answered in the Report
The market is projected to grow at a CAGR of 17.60% between 2022 and 2027.
The major drivers of the market include the presence of numerous large-scale testing laboratories, rising incidence of rheumatoid arthritis, growing biotechnology corporations, increasing focus to develop generic and biosimilar products, rise in approvals of the new biosimilars, and growing investments in the research and development of the new adalimumab biosimilars.
The growing geriatric population and proliferation of skin disorders are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different products are exemptia, adalirel, and cipleumab, among others.
The several distribution channels in the global adalimumab biosimilar market are hospital pharmacies and retail pharmacies, among others.
The major players in the industry are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.
Analyst Review
The growing geriatric population drives the global adalimumab biosimilar market. Aided by the rising incidence of rheumatoid arthritis and the proliferation of skin disorders, the market is expected to grow at a CAGR of 17.60% in the forecast period of 2022-2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different products are exemptia, adalirel, and cipleumab, among others. The several distribution channels of the market are hospital pharmacies and retail pharmacies, among others. The major regional markets for the adalimumab biosimilar are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the global adalimumab biosimilar market are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The India biosimilar market size reached a value of almost USD 633 million in the year 2020. The market is further expected to grow at a CAGR of 11% between 2021 and 2026.
The global prothrombin complex concentrate (PCC) market is being driven by the clinical advantage of PCC over fresh frozen plasma in the historical period. Aided by the widespread use of vitamin K ant...
The global human insulin market attained a value of USD 36 billion in 2020, driven by the rising incidence of diabetes and the increasing geriatric population. Aided by the growing medical and biotech...
The global biosimilar market size reached a value of almost USD 16.6 billion in the year 2020. The biosimilar market is further expected to grow at a CAGR of 18.1% between 2021 and 2026 to reach a val...
The Europe biosimilar market attained a value of USD 2,945 million in the year 2020 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expi...
NEWSLETTER